Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31609761 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCR5ALDH1A1MAOB | |
| SCHEMBL202627 | 0.83 | MAOB (0.56) | MEN1KMT2AMAOBMRGPRX4LMNA | |
| SCHEMBL2707335 | 0.82 | MRGPRX4 (0.54) | MAOBMAOAMRGPRX4 | |
| SCHEMBL2705640 | 0.81 | MRGPRX4 (0.52) | MAOBMRGPRX4HTR1ALMNAHTT | |
| SCHEMBL202507 | 0.81 | MRGPRX4 (0.53) | CCR5MAOBMRGPRX4LMNAHTT | |
| SCHEMBL201800 | 0.80 | PPARG (0.44) | MEN1KMT2ALMNA | |
| SCHEMBL19285699 | 0.80 | KDM1A (0.50) | MRGPRX4LMNAHTT | |
| SCHEMBL2704584 | 0.80 | MRGPRX4 (0.48) | MRGPRX4LMNAHTT | |
| SCHEMBL2706579 | 0.80 | MRGPRX4 (0.57) | CCR5MRGPRX4LMNAHTT | |
| SCHEMBL2705646 | 0.79 | SIRT2 (0.49) | MAOBMRGPRX4LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | MEN1 1037/4885KMT2A 380/4885CCR5 2149/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | MEN1 678/4885KMT2A 1011/4885CCR5 1795/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | MEN1 1027/4885KMT2A 415/4885CCR5 2083/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | MEN1 678/4885KMT2A 1011/4885CCR5 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.